ArticleAdvances in therapy2026
Design of a New Predictive Equation for the Induction Dose of Tacrolimus in Immediate Renal Transplantation.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionKidney transplantation is the treatment of choice for end-stage chronic kidney failure. It requires pharmacological immunosuppressive therapy to prevent graft rejection while minimizing adverse effects. Tacrolimus (TAC) is one of the most widely used agents in this setting. The aim of this study was to determine the proportion of patients achieving optimal TAC concentrations with a 0.10 mg/kg/12 h regimen, identify factors influencing this outcome, and develop a predictive model to optimize dosing.
methodsThis retrospective observational study included kidney transplant recipients treated at Hospital General Universitario de Elche between January 2019 and January 2024.
resultsNinety-three patients were analyzed, including 56 men and 37 women. Demographic, clinical, and pharmacotherapeutic data were collected. Regression analysis showed TAC levels were associated with weight, body mass index, hematocrit, total proteins, and glutamate-pyruvate transaminase (GPT). Only 30% (26 patients) achieved optimal TAC concentrations with the current dosing formula during the initial pharmacokinetic monitoring. However, this study developed a new predictive formula that could theoretically enable better initial dosing adjustments in up to 76% (71) patients.
conclusionThe current TAC dosing framework can be improved and adapted to the specific patient population being treated. In this regard, although the number of patients is low and additional internal and external validations are needed, the new formula developed in this study not only improves the accuracy of prediction results but is also flexible and adaptable enough for use in other clinical settings. Graphical Abstract available for this article.
Indexed as
Identifiers
42720726What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.